SANGSTAT MEDICAL CORP risk profile
50 Elevated one input has moved against it
Measured 21 October 2026 from SANG's filed statements. Recomputed nightly.
50 (Elevated), driven by Competitive position at 59, over 5 weighted categories on the SOFTWARE profile.
What is measured
| Mechanism | Reading | Band | Direction | Driver |
|---|---|---|---|---|
| Market expectation | 50 | Elevated | Volatile | One-year price volatility — 54.3% |
| Operating pressure | 38 | Normal | Easing | Costs outgrowing revenue — +0.1 percentage points |
| Cash conversion | 20 | Normal | Stable | Capital spending against operating cash — 0.21x |
| Leverage and coverage | 32 | Normal | Easing | Current ratio — 0.86x |
| Competitive position | 59 | Elevated | Stable | Operating-margin gap against peers — -5.8 percentage points |
| Concentration | Reads identified supplier spend, customers above the 10% disclosure threshold and revenue by region. No reading is stored for this company. | |||
These are descriptive readings of disclosed mechanisms, not investment advice, and not a prediction. A band says where a measured input sits, never what to do about it or what happens next.
Technology companies with a risk reading
NVIDIA Corp 43Apple Inc 47Microsoft Corporation 33Taiwan Semiconductor Manufacturing 17Broadcom Inc 29Micron Technology Inc 42Advanced Micro Devices Inc 29ASML HOLDING 25ASML Holding NV 26Palantir Technologies Inc - Class A 17Intel Corp 54Cisco Systems Inc 57
Financials, valuation and price history for SANGSTAT MEDICAL CORP